Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Subcutaneous ALXN1830 in Healthy Participants
NCT05254613Phase 1Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2019
- Primary completion
- Jan 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of orilanolimab in warm autoimmune hemolytic anemia (wAIHA), myasthenia gravis (MG) and pemphigus (7 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Treatment Emergent Adverse Events at Day 64. Started Nov 2019; status: terminated.
02
Drugs
orilanolimab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)myasthenia gravis (MG)pemphigus
Beyond the preview
Go deeper on NCT05254613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05254613.